LIMINATUS PHARMA, INC. Increase (Decrease) in Due to Related Parties, Current
LIMINATUS PHARMA, INC. (LIMN) reported Increase (Decrease) in Due to Related Parties, Current of -$8.15 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent · last filed 2026-08-14
- LIMINATUS PHARMA, INC. increase (decrease) in due to related parties, current for the quarter ending 2026-06-30 was $6.84K.
- LIMINATUS PHARMA, INC. increase (decrease) in due to related parties, current for the quarter ending 2026-03-31 was -$15.00K.
- LIMINATUS PHARMA, INC. increase (decrease) in due to related parties, current for the quarter ending 2025-12-31 was $31.53K.
- LIMINATUS PHARMA, INC. increase (decrease) in due to related parties, current for the quarter ending 2025-09-30 was $7.50K.
| Period end | Increase (Decrease) in Due to Related Parties, Current 3 month | Increase (Decrease) in Due to Related Parties, Current 6 month | Increase (Decrease) in Due to Related Parties, Current 9 month | Increase (Decrease) in Due to Related Parties, Current 12 month |
|---|---|---|---|---|
| 2026-06-30 | $6.84K derived: 10-Q 6 month − S-1 3 month · filed 2026-08-14 | -$8.15K 10-Q · filed 2026-08-14 | $23.38K derived: sum of 3 quarters · filed 2026-08-14 | $30.88K derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | -$15.00K S-1 · filed 2026-06-24 | $16.53K derived: sum of 2 quarters · filed 2026-06-24 | $24.03K derived: sum of 3 quarters · filed 2026-06-24 | -$59.47K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $31.53K derived: S-1 12 month − 10-Q 9 month · filed 2026-06-24 | $39.03K derived: sum of 2 quarters · filed 2026-06-24 | -$44.47K derived: sum of 3 quarters · filed 2026-08-14 | -$62.47K S-1 · filed 2026-06-24 |
| 2025-09-30 | $7.50K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$76.00K derived: sum of 2 quarters · filed 2026-08-14 | -$94.00K 10-Q · filed 2025-11-14 | |
| 2025-06-30 | -$83.50K derived: 10-Q 6 month − S-1 3 month · filed 2026-08-14 | -$101.50K 10-Q · filed 2026-08-14 | ||
| 2025-03-31 | -$18.00K S-1 · filed 2026-06-24 | |||
| 2024-09-30 | -$2.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$9.00K 10-Q · filed 2025-11-14 | ||
| 2024-06-30 | -$7.00K 10-Q · filed 2025-10-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |